Arcus Biosciences announced it has inked an option and license deal with Taiho Pharmaceutical Co. to develop and commercialize product candidates in Arcus’s portfolio in Japan and specific Asian territories excluding China.

There is a ray of sunshine for beleaguered Tesaro as Japanese pharma giant Takeda Pharmaceutical struck a deal worth up to $340 million for Asian development and marketing rights for recently approved PARP inhibitor Zejula (niraparib).

Biopharmaceutical company Celgene Corp. will buy a stake in BeiGene Ltd. and help develop and commercialize BeiGene’s investigational treatment for tumor cancers.

Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.

Scientists have found a single class of drugs that can kill the parasites responsible for three tropical diseases that affect millions in Africa, Asia and Latin America.

A study examining genes of more than 120,000 people from Europe, Asia, Africa and the Americas has offered the clearest picture yet of those that drive type 2 diabetes.

A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs.

– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]